SynthesisMedicine2020
Traditional chinese medicine for diabetic retinopathy: A systematic review and meta-analysis.
Synthesis in Medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Pooled it
- Effect of Chinese herbal compounds on ocular fundus signs and vision in conventional treated-persons with non-proliferative diabetic retinopathy: A systematic review and meta-analysis.Frontiers in endocrinology · 2022Pooled it
- Efficacy and Safety of Qiming Granule for Nerve Injury Associated with Non-proliferative Diabetic Retinopathy: A Multicenter, Randomized, Non-inferiority, Active-Controlled Clinical Trial.Chinese journal of integrative medicine · 2026Trial
- Guidelines for visual cognitive rehabilitation of visual information processing disorders (2025).International journal of ophthalmology · 2026Article
- An evidence mapping study based on systematic reviews of traditional Chinese medicine (TCM) for diabetic retinopathy.Systematic reviews · 2025Article
- Perceptions of diabetic retinopathy patients on the management of diabetic retinopathy (DR) in South Tarawa, Kiribati: A qualitative study.PLOS global public health · 2025Article
- Ameliorative effect and potential mechanism of hyperoside on diabetic retinopathy.Frontiers in endocrinology · 2025Article
- Associations of ALT, AST and ALT/AST ratio with metabolically unhealthy obesity in the elderly.Frontiers in nutrition · 2025Article
- PDZD8 Augments Endoplasmic Reticulum-Mitochondria Contact and Regulates Ca2+ Dynamics and Cypd Expression to Induce Pancreatic β-Cell Death during Diabetes.Diabetes & metabolism journal · 2024Article
- Study on the bioactive ingredients and mechanism of Huangqi against diabetic retinopathy based on network pharmacology and experimental verification.Journal of the Chinese Medical Association : JCMA · 2024Article
- Investigation of the reasons for delayed presentation in proliferative diabetic retinopathy patients.PloS one · 2024Article
- HHO optimized support vector machine classifier for traditional Chinese medicine syndrome differentiation of diabetic retinopathy.International journal of ophthalmology · 2024Article
- Stachydrine Relieved the Inflammation and Promoted the Autophagy in Diabetes Retinopathy Through Activating the AMPK/SIRT1 Signaling Pathway.Diabetes, metabolic syndrome and obesity : targets and therapy · 2023Article
- Efficacy and safety of curcumin in diabetic retinopathy: A protocol for systematic review and meta-analysis.PloS one · 2023Article
- Exploration of the Potential Mechanisms of Lingqihuangban Granule for Treating Diabetic Retinopathy Based on Network Pharmacology.Combinatorial chemistry & high throughput screening · 2023Article
- International Diagnostic Guidelines for Blood-Stasis Syndrome.Chinese journal of integrative medicine · 2022Article
- Jiangtang Sanhao formula ameliorates skeletal muscle insulin resistanceFrontiers in pharmacology · 2022Article
- A Network Pharmacology to Explore the Mechanism ofEvidence-based complementary and alternative medicine : eCAM · 2020Article
- Luo Tong Formula Alleviates Diabetic Retinopathy in Rats Through Micro-200b Target.Frontiers in pharmacology · 2020Article
- Non-prescription sale of antibiotics and service quality in community pharmacies in Guangzhou, China: A simulated client method.PloS one · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTraditional Chinese medicine (TCM) has been used to treat diabetic complications including diabetic retinopathy for many years.
objectivesThis review was performed to systematically assess the efficacy and safety of TCM for treating non- proliferative diabetic retinopathy (NPDR).
methodsRetrieval from 7 electronic databases was conducted to determine eligible trials published until March 1, 2018. Randomized controlled trials of NPDR that comparing compound Chinese medicine containing the therapeutic method of activating blood and remove stasis versus controls were included for analysis. Primary outcomes were progression of retinopathy. Secondary outcomes included visual acuity, mean defect of visual field, micro-aneurysms, hemorrhage areas, exudates, capillary nonperfusion areas, hemorheological indicators, oscillatory potentials (Ops), glycated haemoglobin (HbA1c), and adverse events. Data extraction and quality assessment were performed. Results expressing as risk ratios (RRs) or mean differences (MD) were analyzed with a fixed- or random- effect model. I statistics were used to assess heterogeneity.
resultsA total of 33 trials and 3373 participants were included. Findings revealed that no included studies reported the progression of retinopathy. Compared with conventional medicine, TCM was significantly better at improving visual acuity (MD, -0.10; 95% confidence interval [CI] -0.16 to -0.05) and Ops (MD, -4.68, 95% CI -8.51 to -0.85), and reducing the mean defect of visual field (MD, -1.43; 95%CI, -2.17 to -0.68), micro-aneurysms (MD, -4.51; 95% CI, -6.23 to -2.79), hemorrhage areas (MD, -0.62; 95% CI, -1.06 to -0.19), plasma viscosity (MD, -0.10; 95% CI, -0.20 to 0.00), and HbA1c (MD, -0.22; 95% CI, -0.42 to -0.03). Compared with placebo, TCM was also associated with a decline in the number of microaneurysms (MD, -4.35; 95% CI, -6.25 to -2.45), exudates (MD, -0.17; 95% CI -0.31 to -0.03), capillary nonperfusion areas (MD, -0.18; 95% CI, -0.31 to -0.04), and HbA1c (MD, -0.88; 95% CI, -1.44 to -0.32). Compared with blank groups, TCM was superior at decreasing the mean defect of visual field (MD, -0.87; 95% CI -0.95 to -0.79) and the numbers of micro-aneurysms (MD, -3.35; 95% CI, -4.73 to -1.97). Adverse events were also assessed.
conclusionActivating blood compound Chinese herbal medicine could help to improve visual acuity, micro-aneurysms and HbA1c. Further trials are needed to provide more reliable evidence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.